Publication Name	World Journal of Gastrointestinal Pathophysiology
Manuscript ID	4260
Country	Tunisia

Received	2013-06-24 09:51
Peer-Review Started
To Make the First Decision
Return for Revision
Revised
Second Decision	2013-08-06 08:30
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-08-06 11:35
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-08-06 18:21
Publish the Manuscript Online	2013-08-09 16:10

ISSN	2150-5330 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Hematology
Manuscript Type	Case Report
Article Title	Severe hemorrhagic colitis in a patient with chronic myeloid leukemia in the blastic phase after dasatinib use
Manuscript Source	Invited Manuscript
All Author List	Zahra Kmira, Ben Sayed Nesrine, Zaghouani Houneida, Ben Fredj Wafa, Slama Aida, Ben Youssef Yosra, Zaier Monia, Badreddine Sriha and Khelif Abderrahim
Funding Agency and Grant Number
Corresponding Author	Dr. Zahra Kmira, Department of Clinical Hematology, University Hospital Farhat Hached, Avenue Ibn Eljazzar, Sousse 4000, Tunisia. kmira_zahra@yahoo.fr
Key Words	Philadelphia chromosome; Chronic myeloid leukemia; Dasatinib; Colitis
Core Tip	Dasatinib is a second-line tyrosine kinase inhibitor used in imatinib resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute leukemia patients. Dasatinib, which binds to the active and inactive conformation of the BCR-ABL oncoprotein, demonstrates greater potency than imatinib for wild-type and mutant BCR-ABL cases, with the exception of the T315I mutation. The most frequent adverse effects include myelosuppression, diarrhea, nausea and peripheral edema. Severe dasatinib-relatedacute colitis without thrombocytopenia, coagulation abnormalities or colonic ulcers has rarely been reported. Here, we report the case of an adult patient with Philadelphia chromosome positive CML in the blastic phase who developed acute colitis after dasatinib use.
Publish Date	2013-08-09 16:10
Citation	Kmira Z, Nesrine BS, Houneida Z, Wafa BF, Aida S, Yosra BY, Monia Z, Sriha B, Abderrahim K. Severe hemorrhagic colitis in a patient with chronic myeloid leukemia in the blastic phase after dasatinib use. World J Gastrointest Pathophysiol 2013; 4(3): 59-62
URL	http://www.wjgnet.com/2150-5330/full/v4/i3/59.htm
DOI	http://dx.doi.org/10.4291/wjgp.v4.i3.59

Full Article (PDF)	WJGP-4-59.pdf
Manuscript File	4260-Review.docx
Answering Reviewers	4260-Answering reviewers.pdf
Copyright License Agreement	4260-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	4260-Language certificate.pdf
Peer-review Report	4260-Peer review(s).pdf
Scientific Editor Work List	4260-Scientific editor work list.doc